Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients

Better prognostication of graft and patient outcomes among kidney transplant recipients with post-transplant lymphoproliferative disease (PTLD) in the rituximab era is needed to inform treatment decisions. Therefore, we sought to estimate the excess risks of death and graft loss in kidney transplant recipients with PTLD, and to determine risk factors for death. Using the ANZDATA registry, the risks of mortality and graft loss among recipients with and without PTLD were estimated using survival analysis.

Source: Kidney International - August 30, 2018 Category: Urology & Nephrology Authors: Anna Francis, David W. Johnson, Jonathan Craig, Armando Teixeira-Pinto, Germaine Wong Tags: Clinical Investigation Source Type: research